Gutenberg Open Science: Smartglass augmented reality-assisted targeted prostate biopsy using cognitive point-of-care fusion technology

Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-8632

Full metadata record

DC Field	Value	Language
dc.contributor.author	Sparwasser, Peter	-
dc.contributor.author	Haack, Maximilian	-
dc.contributor.author	Epple, Stefan	-
dc.contributor.author	Frey, Lisa	-
dc.contributor.author	Zeymer, Steffen	-
dc.contributor.author	Dotzauer, Robert	-
dc.contributor.author	Jungmann, Florian	-
dc.contributor.author	Böhm, Katharina	-
dc.contributor.author	Höfner, Thomas	-
dc.contributor.author	Tsaur, Igor	-
dc.contributor.author	Haferkamp, Axel	-
dc.contributor.author	Borgmann, Hendrik	-
dc.date.accessioned	2023-01-24T09:57:55Z	-
dc.date.available	2023-01-24T09:57:55Z	-
dc.date.issued	2022	-
dc.identifier.uri	https://openscience.ub.uni-mainz.de/handle/20.500.12030/8648	-
dc.description.abstract	Introduction MRI-guided targeted biopsy has become standard of care for diagnosis of prostate cancer, with establishment of several biopsy techniques and platforms. Augmented reality smart glasses have emerged as novel technology to support image-guided interventions. We aimed to investigate its usage while prostate biopsy. Methods MRI with PIRADS-lesions ≥3 was uploaded to smart glasses (Vuzix BladeR) and augmented reality smart glasses-assisted targeted biopsy (SMART-TB) of the prostate was performed using cognitive fusion technology at the point of care. Detection rates were compared to systematic biopsy. Feasibility for SMART-TB was assessed (10 domains from bad [1] to excellent [10]). Results SMART-TB was performed for four patients. Prostate cancer detection was more likely for SMART-TB (46%; 13/28) than for systematic biopsy (27%; 13/48). Feasibility scores were high [8–10] for practicality, multitasking, execution speed, comfort and device weight and low [1–4] for handling, battery and image quality. Median execution time: 28 min; Investment cost smart glass: 1017 USD. Conclusion First description of SMART-TB demonstrated convenient feasibility. This novel technology might enhance diagnosis of prostate cancer in future.	en_GB
dc.description.sponsorship	Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 491381577	de
dc.language.iso	eng	de
dc.rights	CC BY-NC-ND	*
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.subject.ddc	610 Medizin	de_DE
dc.subject.ddc	610 Medical sciences	en_GB
dc.title	Smartglass augmented reality-assisted targeted prostate biopsy using cognitive point-of-care fusion technology	en_GB
dc.type	Zeitschriftenaufsatz	de
dc.identifier.doi	http://doi.org/10.25358/openscience-8632	-
jgu.type.dinitype	article	en_GB
jgu.type.version	Published version	de
jgu.type.resource	Text	de
jgu.organisation.department	FB 04 Medizin	de
jgu.organisation.number	2700	-
jgu.organisation.name	Johannes Gutenberg-Universität Mainz	-
jgu.rights.accessrights	openAccess	-
jgu.journal.title	The international journal of medical robotics and computer assisted surgery	de
jgu.journal.volume	18	de
jgu.journal.issue	3	de
jgu.pages.alternative	e2366	de
jgu.publisher.year	2022	-
jgu.publisher.name	Wiley	de
jgu.publisher.place	Chichester	de
jgu.publisher.issn	1478-596X	de
jgu.organisation.place	Mainz	-
jgu.subject.ddccode	610	de
jgu.publisher.doi	10.1002/rcs.2366	de
jgu.organisation.ror	https://ror.org/023b0x485	-
jgu.subject.dfg	Lebenswissenschaften	de
Appears in collections:	DFG-491381577-H

Files in This Item:

	File	Description	Size	Format
	smartglass_augmented_realitya-20230124104352954.pdf		448.12 kB	Adobe PDF	View/Open

Show simple item record